RG
CPRX

Renaissance Group’s Catalyst Pharmaceutical CPRX Stock Holding History

Renaissance Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11M Buy
445,215
+98,847
+29% +$2.35M 0.46% 63
2025
Q4 		$8.08M Sell
346,368
-9,654
-3% -$215K 0.32% 78
2025
Q3 		$7.01M Buy
356,022
+26,965
+8% +$555K 0.26% 111
2025
Q2 		$7.14M Buy
329,057
+76,772
+30% +$1.81M 0.28% 87
2025
Q1 		$6.12M Buy
252,285
+49,525
+24% +$1.12M 0.27% 81
2024
Q4 		$4.23M Buy
+202,760
New +$4.36M 0.18% 105

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Renaissance Group's CPRX Position: Q1 2026 in Review

Renaissance Group increased its Catalyst Pharmaceutical (CPRX) stake by 29% in Q1 2026, buying an estimated $2.35M and bringing the position to 445,215 shares worth $11M. The position accounts for 0.46% of the portfolio, ranked #63.

Renaissance Group first reported a position in CPRX in Q4 2024 and has held it in 6 quarters since. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Renaissance Group held 445,215 shares of Catalyst Pharmaceutical worth $11M as of Q1 2026.
  • Renaissance Group bought 98,847 Catalyst Pharmaceutical shares in Q1 2026, an estimated $2.35M.
  • Catalyst Pharmaceutical made up 0.46% of Renaissance Group's portfolio in Q1 2026, its #63 holding.
  • Renaissance Group first reported a position in Catalyst Pharmaceutical in Q4 2024 and has held it in 6 quarters since.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Renaissance Group's 13F filing for Q1 2026, filed 13 May 2026.